Daniel Vittecoq

Summary

Country: France

Publications

  1. ncbi request reprint Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era
    Daniel Vittecoq
    Service des Maladies Infectieuses et de Médecine Interne, Hopital Paul Brousse, Villejuif, France
    AIDS 17:S70-6. 2003
  2. ncbi request reprint [Liver transplantation: is it possible in HIV/HCV co-infected patients?]
    D Vittecoq
    Service des Maladies Infectieuses, Hopital Paul Brousse, 12 14, avenue Paul Vaillant Couturier, 94800 Villejuif, France
    Pathol Biol (Paris) 51:525-7. 2003
  3. ncbi request reprint Coronary heart disease in HIV-infected individuals
    Daniel Vittecoq
    Service des Maladies Infectieuses, Hopital Paul Brousse, Villejuif, France
    Adv Cardiol 40:151-62. 2003
  4. doi request reprint Enfuvirtide: a safe and effective antiretroviral agent for human immunodeficiency virus-infected patients shortly after liver transplantation
    Elina Teicher
    Département Médecine Interne et Infectiologie, AP HP Hopital Paul Brousse, Villejuif, France
    Liver Transpl 15:1336-42. 2009
  5. ncbi request reprint Coronary artery disease in HIV infected patients
    Lelia Escaut
    Service des Maladies Infectieuses, Hopital Paul Brousse, 12 14 avenue Paul Vaillant Couturier, 94804, Villejuif, France
    Intensive Care Med 29:969-73. 2003
  6. ncbi request reprint Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study
    Elina Teicher
    Internal Medicine and Infectious Diseases Department, Hopital Paul Brousse, Assistance Publique Hopitaux de Paris AP HP, Paris, France
    Clin Pharmacokinet 46:941-52. 2007
  7. ncbi request reprint Relationship between polymerase gamma (POLG) polymorphisms and antiretroviral therapy-induced lipodystrophy in HIV-1 infected patients: a case-control study
    Franck Chiappini
    AP HP, Hopital Paul Brousse, Service de Biochimie et de Biologie Moléculaire, Université Paris 11, 12, avenue Paul Vaillant Couturier, Villejuif Cedex, France
    Curr HIV Res 7:244-53. 2009
  8. doi request reprint Efficacy of etravirine for treatment of acute HIV meningoencephalitis
    Carine Couzigou
    Services des Maladies Infectieuses et Tropicales and Virologie, Assistance Publique Hôpital de Paris, Hopital Paul Brousse, Villejuif, France
    Clin Infect Dis 48:e62-5. 2009
  9. ncbi request reprint Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus
    Jean Charles Duclos-Vallée
    Centre Hepato Biliaire, AP HP Hopital Paul Brousse, Villejuif, France
    Hepatology 47:407-17. 2008
  10. ncbi request reprint [Liver transplantation for patients infected with both HIV and HCV or HIV and HBV]
    Jean Charles Duclos-Vallée
    Département des Maladies du Foie et INSERM U785, Unité de maladies infectieuses, Universite Paris XI, Centre Hepato Biliaire, Hopital Paul Brousse, 12 14, avenue Paul Vaillant Couturier, 94804, Villejuif, France
    Med Sci (Paris) 23:723-8. 2007

Detail Information

Publications29

  1. ncbi request reprint Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era
    Daniel Vittecoq
    Service des Maladies Infectieuses et de Médecine Interne, Hopital Paul Brousse, Villejuif, France
    AIDS 17:S70-6. 2003
    ..To assess the incidence and the clinical features of coronary heart disease in HIV-infected patients. To assess atherosclerosis risk factors in this population...
  2. ncbi request reprint [Liver transplantation: is it possible in HIV/HCV co-infected patients?]
    D Vittecoq
    Service des Maladies Infectieuses, Hopital Paul Brousse, 12 14, avenue Paul Vaillant Couturier, 94800 Villejuif, France
    Pathol Biol (Paris) 51:525-7. 2003
    ..Finally, liver transplantation in HIV-HCV co-infected patients seems to be feasible when strict criteria of selection are taken into account. This still experimental strategy requires a multidisciplinary partnership...
  3. ncbi request reprint Coronary heart disease in HIV-infected individuals
    Daniel Vittecoq
    Service des Maladies Infectieuses, Hopital Paul Brousse, Villejuif, France
    Adv Cardiol 40:151-62. 2003
  4. doi request reprint Enfuvirtide: a safe and effective antiretroviral agent for human immunodeficiency virus-infected patients shortly after liver transplantation
    Elina Teicher
    Département Médecine Interne et Infectiologie, AP HP Hopital Paul Brousse, Villejuif, France
    Liver Transpl 15:1336-42. 2009
    ..Moreover, the lack of liver toxicity renders this drug valuable in the event of a severe HCV recurrence...
  5. ncbi request reprint Coronary artery disease in HIV infected patients
    Lelia Escaut
    Service des Maladies Infectieuses, Hopital Paul Brousse, 12 14 avenue Paul Vaillant Couturier, 94804, Villejuif, France
    Intensive Care Med 29:969-73. 2003
    ..To assess the incidence, clinical features, treatment, and follow-up of coronary events in HIV-infected patients over a period of 5 years...
  6. ncbi request reprint Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study
    Elina Teicher
    Internal Medicine and Infectious Diseases Department, Hopital Paul Brousse, Assistance Publique Hopitaux de Paris AP HP, Paris, France
    Clin Pharmacokinet 46:941-52. 2007
    ..To characterise the interactions between tacrolimus and antiretroviral drug combinations in hepatitis C virus-HIV co-infected patients who had received a liver transplant...
  7. ncbi request reprint Relationship between polymerase gamma (POLG) polymorphisms and antiretroviral therapy-induced lipodystrophy in HIV-1 infected patients: a case-control study
    Franck Chiappini
    AP HP, Hopital Paul Brousse, Service de Biochimie et de Biologie Moléculaire, Université Paris 11, 12, avenue Paul Vaillant Couturier, Villejuif Cedex, France
    Curr HIV Res 7:244-53. 2009
    ..These could be due to decreased content of mtDNA in PBMC in these patients. Therefore, the toxicity of NRTIs leading to lipodystrophy in some HIV-1 infected patients could be explained in part by the occurrence of POLG polymorphisms...
  8. doi request reprint Efficacy of etravirine for treatment of acute HIV meningoencephalitis
    Carine Couzigou
    Services des Maladies Infectieuses et Tropicales and Virologie, Assistance Publique Hôpital de Paris, Hopital Paul Brousse, Villejuif, France
    Clin Infect Dis 48:e62-5. 2009
    ..Etravirine has a satisfactory safety profile and, in this case, was a durable alternative therapy for HIV meningoencephalitis...
  9. ncbi request reprint Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus
    Jean Charles Duclos-Vallée
    Centre Hepato Biliaire, AP HP Hopital Paul Brousse, Villejuif, France
    Hepatology 47:407-17. 2008
    ..03; risk ratio, 1.08; 95% confidence interval, 1.01, 1.15). Using the Kaplan-Meier method, the progression to fibrosis >or= F2 was significantly higher in the coinfected group (P < 0.0001)...
  10. ncbi request reprint [Liver transplantation for patients infected with both HIV and HCV or HIV and HBV]
    Jean Charles Duclos-Vallée
    Département des Maladies du Foie et INSERM U785, Unité de maladies infectieuses, Universite Paris XI, Centre Hepato Biliaire, Hopital Paul Brousse, 12 14, avenue Paul Vaillant Couturier, 94804, Villejuif, France
    Med Sci (Paris) 23:723-8. 2007
    ..Understanding HCV recurrence mechanisms, and preventing and treating of HCV recurrence are major future challenges...
  11. ncbi request reprint Cytokines in HIV-associated cardiomyopathy
    Jean Jacques Monsuez
    AP HP, Hopital Paul Brousse, Department of Internal Medicine and Infectious Diseases, Universite Paris Sud 11, Faculte de Medecine, de Bicêtre, France 94804 Villejuif, France
    Int J Cardiol 120:150-7. 2007
    ..Whether modulation of TNF production or selective inhibition of p38 MAPK pathway could be useful approaches remains uncertain...
  12. ncbi request reprint Non-O:1 and non-O:139 Vibrio cholerae septicemia and pyomyositis in an immunodeficient traveler returning from Tunisia
    Carine Couzigou
    Unit of Infectious Diseases and Tropical Medicine, Faculte de Medecine Paris XII, Assistance Publique Hopitaux de Paris, Hopital Paul Brousse, 12 avenue PV Couturier, 94804 Villejuif, France
    Travel Med Infect Dis 5:44-6. 2007
  13. ncbi request reprint Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study
    Hassane Izzedine
    Department of Nephrology, Pitie Salpetriere Hospital, 47 83 boulevard de l Hopital, 75013 Paris, France
    Nephrol Dial Transplant 20:743-6. 2005
    ..However, controlled data are sparse on the long-term renal tolerability of TDF at the currently approved daily dose of 300 mg in treatment-naive HIV-infected patients...
  14. ncbi request reprint Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIV-HCV co-infected patients
    Jean Charles Duclos-Vallée
    Centre Hépato Biliaire Hôpital Paul Brousse, Assistance Publique Hopitaux de Paris, 94804 Villejuif, France
    J Hepatol 42:341-9. 2005
    ..We report the Paul Brousse Hospital experience of transplantation for end stage cirrhosis in HIV-HCV co-infected patients...
  15. ncbi request reprint [Liver transplantation in patients with HIV: indications, limits, perspectives]
    Didier Samuel
    Centre Hepatobiliaire, UPRES 3541, Formation Associée de Recherche Association Claude Bernard Virus et Transplantation, Universite Paris Sud
    Gastroenterol Clin Biol 27:372-4. 2003
  16. pmc Enhanced saquinavir exposure in human immunodeficiency virus type 1-infected patients with diarrhea and/or wasting syndrome
    Hervé Trout
    Laboratoire de Toxicologie et Pharmacologie Clinique, Service de Pharmacie, Hopital Lariboisiere, Paris, France
    Antimicrob Agents Chemother 48:538-45. 2004
    ..This must be evaluated in a long-term period...
  17. ncbi request reprint Prospective evaluation of blood concentration of mitochondrial DNA as a marker of toxicity in 157 consecutively recruited untreated or HAART-treated HIV-positive patients
    Franck Chiappini
    Service de Biochimie et de Biologie Moléculaire INSERM 602, Hopital Paul Brousse, 12 avenue Paul Vaillant Couturier, 94800 Villejuif, France
    Lab Invest 84:908-14. 2004
    ..Thus, the mtDNA to nDNA ratio in leukocytes does not seem to be an accurate marker of mild and/or long-term mitochondrial toxicity...
  18. ncbi request reprint Liver transplantation in patients with HIV infection
    Didier Samuel
    Centre Hepatobiliaire, UPRES 3541, Recherche Association Claude Bernard Virus et Transplantation, Universite Paris Sud, Hopital Paul Brousse, AP HOP Paris, 14 avenue Paul Vaillant Couturier, 94800 Villejuif, France
    J Hepatol 39:3-6. 2003
  19. ncbi request reprint Mitochondrial damage associated with long-term antiretroviral treatment: associated alteration or causal disorder?
    Daniel Vittecoq
    Unité des maladies infectieuses, Hopital Paul Brousse, Villejuif, France
    J Acquir Immune Defic Syndr 31:299-308. 2002
    ..Its severity argues for its clinical relevance, however. The skewed tissue distribution of mitochondrial alterations indicates potential pitfalls in the needed future prospective studies...
  20. doi request reprint Initial human herpesvirus-8 rash and multicentric Castleman disease
    Benjamin Wyplosz
    Unité des Maladies Infectieuses et Tropicales, Hopital Paul Brousse, Villejuif, Paris, France
    Clin Infect Dis 47:684-8. 2008
    ..We document the first case, to our knowledge, of HHV-8-induced rash and suggest that circulating plasmablasts drive HHV-8 to target tissues...
  21. ncbi request reprint Urolithiasis in HIV-positive patients treated with atazanavir
    Carine Couzigou
    Service des Maladies Infectieuses et Tropicales, AP HP, Hopital Paul Brousse, Villejuif, France
    Clin Infect Dis 45:e105-8. 2007
    ..Patients with low water intake, high urinary pH, and a prior history of urinary stones may have a higher risk of atazanavir-associated urine crystallization...
  22. ncbi request reprint [Anti-Jo1 antibodies syndrome in an HIV-infected patient]
    Carine Salliot
    Unité de maladies infectieuses et tropicales, Centre Hospitalier Universitaire Paul Brousse, 14, avenue Paul Vaillant Couturier, BP 200, 94804 Villejuif Cedex, France
    Ann Med Interne (Paris) 153:209-10. 2002
    ..Anti-Jo1 antibodies are exceptional in HIV-infected patients. We discuss the role of infection in polymyositis. HAART and corticosteroids led to rapid clinical and radiological improvement...
  23. ncbi request reprint Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial
    Beatriz Grinsztejn
    Evandro Chagas Clinical Research Institute Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
    Lancet 369:1261-9. 2007
    ..The aim of this study was to assess the safety and efficacy of raltegravir when added to optimised background regimens in HIV-infected patients...
  24. ncbi request reprint Renal safety of tenofovir in HIV treatment-experienced patients
    Hassane Izzedine
    Department of Nephrology, Pitie Salpetriere Hospital, Paris, France
    AIDS 18:1074-6. 2004
    ..Proximal tubulopathy was diagnosed 6.89 +/- 5.51 months after TDF therapy started. All abnormalities normalized within 4.7 +/- 2.94 weeks after drug discontinuation...
  25. ncbi request reprint The pavia consensus statement
    Paul A Volberding
    University of California, San Francisco, USA
    AIDS 17:S170-9. 2003
  26. ncbi request reprint [The HIV-infected traveler: infectious risks and prevention]
    Carine Couzigou
    Service des Maladies Infectieuses et Tropicales, AP HP Hopital Paul Brousse, F 94800 Villejuif, France
    Presse Med 37:490-9. 2008
    ..Some countries have entry restriction for travelers with HIV. Special precautions may be necessary for transporting and storing antiretroviral medications...
  27. pmc Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease
    Karim Sacre
    Laboratoire d Immunologie Cellulaire et Tissulaire, INSERM U543, Hopital Pitie Salpetriere, Universite Pierre et Marie Curie, 75013 Paris, France
    J Exp Med 201:1999-2010. 2005
    ....
  28. ncbi request reprint Brief report: carotid intima-media thickness in heavily pretreated HIV-infected patients
    Gilles Chironi
    Centre de Médecine Préventive Cardiovasculaire and Unité CNRS UMR7131, Hopital Broussais, 96 rue Didot, 75674 Paris Cedex 14, France
    J Acquir Immune Defic Syndr 32:490-3. 2003
    ..This case-control study suggests that lipid disturbances, mainly hypoHDLemia, may be involved in the early atherosclerotic process in HIV-infected patients...
  29. ncbi request reprint Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094)
    Roland Tubiana
    Departement des Maladies Infectieuses et Tropicales, INSERM E0214, Hopital Pitie Salpetriere, Paris, France
    Vaccine 23:4292-301. 2005
    ..Detection of such LPR response at the time of treatment interruption was significantly associated with the probability of remaining off therapy. These results provide rationale for future randomized trials exploring this strategy...